Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839494 | 0.97 | HTT (0.62) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL30605362 | 0.95 | TGM2 (0.57) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL30605293 | 0.94 | HTT (0.58) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL335088 | 0.93 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL4363476 | 0.92 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL235394 | 0.92 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Bicarbonate SCHEMBL10633260 | 0.92 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL3049211 | 0.92 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL2076614 | 0.92 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL19240717 | 0.92 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2035004-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | Parion Sciences, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146869-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | HTT 1824/4885TGM2 4237/4885LMNA 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.